Natco Pharma Ltd.

Natco Pharma has received approval for generic Daclatasvir Dihydrochloride (‘Daclatasvir’) tablets, 30mg & 60mg, from Drugs Controller General (India). Daclatasvir is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection. Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets. This is the first company in India to get approval for generic Daclatasvir Dihydrochloride.

The company will market generic Daclatasvir under its own brand NATDAC and through its strategic partners in India. The company will launch immediately in India at an MRP of Rs 6000 and Rs 4000 for the 60mg and 30mg strengths, respectively, for a bottle of 28 tablets. 

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.